This summary discusses only primary epithelial breast cancers. Rarely, the breast may be involved by other tumors such as lymphomas, sarcomas, or melanomas. (Refer to the PDQ summaries on Adult Hodgkin Lymphoma Treatment, Adult Soft Tissue Sarcoma Treatment, and Melanoma Treatment for more information.)
John W. Anderson has stood by his mother, wife, sister, and his mom’s
closest friend as they battled breast cancer. His new book, Stand by Her: A
Breast Cancer Guide for Men, published in time for National Breast Cancer
Awareness Month, details these experience, and all that he learned by being on
the frontlines of this battle with four of the most important women in his
From when to stay quiet, shave your head, or grab a beer with a buddy to get
out of what he dubs "Cancerland," Anderson...
Estimated new cases and deaths from breast cancer (women only) in the United States in 2013:
New cases: 232,340.
Genetic Characteristics and Risk Factors
Several well-established factors have been associated with an increased risk of breast cancer, including family history, nulliparity, early menarche, advanced age, and a personal history of breast cancer (in situ or invasive).
Age-specific risk estimates are available to help counsel and design screening strategies for women with a family history of breast cancer.[2,3] Of all women with breast cancer, 5% to 10% may have a germ-line mutation of the genes BRCA1 and BRCA2. Specific mutations of BRCA1 and BRCA2 are more common in women of Jewish ancestry. The estimated lifetime risk of developing breast cancer for women with BRCA1 and BRCA2 mutations is 40% to 85%. Carriers with a history of breast cancer have an increased risk of contralateral disease that may be as great as 5% per year. Male carriers of BRCA2 mutations are also at increased risk for breast cancer.
Mutations in either the BRCA1 or BRCA2 gene also confer an increased risk of ovarian cancer.[7,8,9] In addition, mutation carriers may be at increased risk of other primary cancers.[7,9] Genetic testing is available to detect mutations in members of high-risk families.[10,11,12,13,14] Such individuals should first be referred for counseling. (Refer to the PDQ summaries on Genetics of Breast and Ovarian Cancer; Breast Cancer Prevention; and Breast Cancer Screening for more information.)
Clinical trials have established that screening with mammography, with or without clinical breast examination, may decrease breast cancer mortality. (Refer to the PDQ summary on Breast Cancer Screening for more information.)
Patient management following initial suspicion of breast cancer generally includes confirmation of the diagnosis, evaluation of stage of disease, and selection of therapy. At the time the tumor tissue is surgically removed, estrogen receptor (ER) and progesterone receptor (PR) status should be determined.